EVOK Financials 07/21/2014 21:46:20
Evoke Pharma, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue - - -
Cost of Revenue - - -
Gross Profit - - -
Operating Expenses
Research and Development 957 1,166 1,844
Sales, General and Admin. 1,645 837 571
Non-Recurring Items - - -
Other - - -
Operating Income (2,602) (2,002) (2,415)
Income From Continuing Operations
Add'l Income/Expense Items (75) 9 16
Earnings Before Interest and Tax (2,677) (1,993) (2,398)
Interest Expense 160 24 3
Earnings Before Tax (2,836) (2,018) (2,401)
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (2,836) (2,018) (2,401)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (2,836) (2,018) (2,401)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (2,836) (2,018) (2,401)
Evoke Pharma, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue - - -
Cost of Revenue - - -
Gross Profit - - -
Operating Expenses
Research and Development 957 1,166 1,844
Sales, General and Admin. 1,645 837 571
Non-Recurring Items - - -
Other - - -
Operating Income (2,602) (2,002) (2,415)
Income From Continuing Operations
Add'l Income/Expense Items (75) 9 16
Earnings Before Interest and Tax (2,677) (1,993) (2,398)
Interest Expense 160 24 3
Earnings Before Tax (2,836) (2,018) (2,401)
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (2,836) (2,018) (2,401)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (2,836) (2,018) (2,401)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (2,836) (2,018) (2,401)
